The COVID-19 pandemic is considered as the most crucial global health calamity of the century and the greatest challenge that the humankind faced. Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. Taxonomically SARS CoV 2 belongs to the family Coronaviridae, subfamily Coronavirinae and the order Nidovirrales. Subfamily Coronavirinae is divided into four genera- α, β, γ and δ. RBD is a fundamental peptide domain as it represents a binding site for the human angiotensin converting enzyme 2 (ACE2). In the course of treatment of SARS-CoV-2 there are hetergeous response was observed in trials and case studies. The major therapeutic agent was used was immunosuppressants like prednisolone assisted by other drugs which are mainly used other infective disorders but principal was those drug came from drug repurposing. Therapy was segregated in 2 objectives. First objective was to reduce and control the inflammatory responses and second objective was to reduce the viral load which is mainly focuses on the antivirals. Vaccine was also implanted as preventive measures but not proven to be fully prophylactic, in addition the vaccine was proven to control the disease severity that finally reduce the morbidity and mortality. Further research is mandatory specially encompasses on the epidemiological and epigenetical approaches.